TURP and TUeVP for Benign Prostatic Hyperplasia — Cost, Top Hospitals & Success Rates | MyMedicPlus

Transurethral resection of the prostate (TURP) is the long-established surgical gold standard for the treatment of symptomatic benign prostatic hyperplasia (BPH) causing moderate-to-severe lower urinary tract symptoms (LUTS). Transurethral electrovaporisation of the prostate (TUeVP) is a closely related endoscopic technique that uses a grooved or spiked roller electrode to simultaneously vaporise and desiccate prostate tissue, achieving comparable symptomatic relief with reduced intra-operative bleeding.

Benign prostatic hyperplasia is the most common benign tumour in men, affecting more than 50% of men by the age of 60 and up to 90% by the age of 85. Progressive adenomatous enlargement of the transition zone of the prostate compresses the prostatic urethra, creating bladder outlet obstruction that manifests as obstructive and irritative lower urinary tract symptoms: poor urinary stream, straining to void, intermittency, sensation of incomplete bladder emptying, frequency, nocturia, and urgency. Untreated bladder outlet obstruction leads to detrusor muscle decompensation, urinary retention, upper urinary tract dilatation, renal impairment, bladder stones, and recurrent urinary tract infection.

Both TURP and TUeVP are performed cystoscopically through the urethra using a resectoscope. In TURP, a cutting loop removes chips of adenomatous prostate tissue, which are evacuated by continuous irrigation. In TUeVP, the roller electrode vaporises tissue directly without creating resected chips, resulting in a cleaner operative field with less bleeding — an advantage particularly relevant in anticoagulated patients or those with larger prostates where blood loss is a concern. TUeVP has largely been supplanted in many centres by bipolar TURP and by holmium laser enucleation of the prostate (HoLEP), but remains a useful technique in specific patient subsets.

According to the EAU Guidelines on Non-neurogenic Male LUTS, TURP remains the urological surgical procedure with the strongest Level 1 evidence for efficacy and durability, with outcomes maintained at 10–20 years in long-term follow-up studies, and a retreatment rate of approximately 15–20% at 8 years.

TURP and TUeVP are indicated for the following clinical presentations of BPH and related bladder outlet obstruction disorders:

• Moderate-to-severe LUTS secondary to BPH: Patients with an International Prostate Symptom Score (IPSS) of 8 or greater (moderate to severe), in whom quality of life is significantly impaired, and who have failed or declined adequate medical therapy (alpha-blockers and/or 5-alpha reductase inhibitors). TURP consistently achieves reductions in IPSS of 70–85% and improvements in peak urinary flow rate (Qmax) from typically 7–10 mL/s pre-operatively to 20–25 mL/s post-operatively.
• Urinary retention: Acute urinary retention (AUR) — inability to void requiring emergency catheterisation — occurs in 1–2% of men with BPH per year. After an episode of AUR, 30–40% of men fail a trial without catheter on alpha-blocker therapy and require definitive surgical intervention. Recurrent AUR despite maximal medical therapy is an absolute indication for TURP.
• BPH complications: Obstructive uropathy with upper tract dilatation, recurrent urinary tract infections secondary to incomplete bladder emptying, bladder calculi resulting from urinary stasis, and haematuria of prostatic origin are all complications mandating surgical intervention regardless of symptom severity.
• Bladder decompensation: Chronic urinary retention with high post-void residual volumes (greater than 300 mL), impaired detrusor contractility, or bilateral hydronephrosis from prostatic obstruction requires decompression.
• BPH in patients with elevated PSA: When BPH requires surgical treatment and prostate cancer has been excluded (or a concurrent prostate biopsy is negative), TURP provides the additional benefit of histological examination of resected chips, which identifies incidental prostate cancer in 8–10% of cases.

Patient selection for TURP and TUeVP requires careful urological assessment, prostate size determination, medical optimisation, and shared decision-making regarding the expected benefits, risks, and available alternatives.

Standard indications: Patients with moderate-to-severe LUTS (IPSS greater than or equal to 8) and objective evidence of bladder outlet obstruction on urodynamics or flow rate studies, who have failed or declined medical management, or who have developed BPH complications (retention, obstructive uropathy, recurrent UTI, haematuria, or bladder calculi). Medical therapy failure is defined as inadequate symptom response after a minimum 3–6 month trial of alpha-blockers, with or without 5-alpha reductase inhibitors.

Prostate size and technique selection: Standard monopolar TURP is most appropriate for prostate glands of 30–80 mL in volume, with resection time limited to 60–90 minutes to reduce irrigant absorption risk. Bipolar TURP can be safely performed for larger glands (greater than 80 mL) without time pressure due to isotonic saline compatibility. For very large glands (greater than 80–100 mL), HoLEP or open simple prostatectomy may be preferred.

Pre-operative evaluation: Includes serum PSA, serum creatinine and eGFR, urine culture (UTI must be treated pre-operatively), flow rate study with post-void residual measurement, and IPSS questionnaire. Flexible cystoscopy assesses urethral stricture, bladder pathology, and prostatic anatomy. CT or ultrasound estimates prostate volume.

Anticoagulation and antiplatelet management: Direct oral anticoagulants (DOACs), warfarin, and antiplatelet agents are withheld for defined periods pre-operatively according to local protocols and after haematological/cardiological consultation. Bipolar TURP and TUeVP are preferred in patients where anticoagulation interruption is higher risk due to their reduced bleeding profiles.

Anaesthetic fitness: Spinal anaesthesia is preferred as it allows intra-operative assessment of consciousness (aiding detection of TUR syndrome in monopolar cases) and is associated with lower thromboembolic risk. Patients unfit for spinal anaesthesia receive general anaesthesia. Standard ASA-classified pre-operative assessment is performed.

Multiple endoscopic and surgical approaches are available for BPH surgical treatment. The choice between TURP, TUeVP, and alternatives such as HoLEP depends on prostate size, surgeon expertise, available equipment, and patient factors:

1. Monopolar TURP: The traditional technique, developed in the 1920s and refined over decades to become the reference standard against which all other BPH surgical procedures are compared. A monopolar resectoscope loop cuts prostatic adenoma chips using alternating current; the circuit is completed through a skin electrode plate. Glycine or sorbitol-based hypotonic irrigant is required because isotonic saline conducts current and disperses the monopolar electrosurgical energy. This obligates the risk of irrigant absorption and TUR syndrome (dilutional hyponatraemia), historically the most feared complication of the procedure. Despite this, monopolar TURP remains widely performed globally and produces excellent symptom improvement in appropriately selected patients.

2. Bipolar TURP: Uses a bipolar resectoscope in which both active and return electrodes are located at the tip of the resectoscope, completing the electrical circuit locally without a skin electrode. This allows use of isotonic saline (0.9% NaCl) as the irrigant, eliminating the risk of TUR syndrome and dilutional hyponatraemia. Bipolar TURP achieves equivalent efficacy to monopolar TURP in multiple randomised controlled trials and meta-analyses, with significantly lower rates of TUR syndrome (virtually zero), comparable or slightly lower blood transfusion rates, and similar catheterisation times. Bipolar TURP is now the preferred standard at most high-volume centres globally, and the EAU Guidelines recommend it over monopolar TURP where available.

3. Transurethral electrovaporisation of the prostate (TUeVP): Uses a grooved roller or button electrode to vaporise (desiccate and immediately ablate) prostatic tissue layer by layer without producing resection chips. The heat generated by the high-power current creates a coagulation zone that provides superior haemostasis compared to standard TURP loop resection. TUeVP is particularly useful in patients with coagulopathy, those on anticoagulation that cannot be fully reversed, or for surgeons treating larger glands where blood loss is a concern. Disadvantage: no tissue chips are produced for histopathological examination (routine PSA and pre-operative biopsy protocols therefore become more important). Efficacy is comparable to standard TURP in randomised trials.

4. Holmium laser enucleation of the prostate (HoLEP): An emerging technique — now considered the new gold standard for large-volume prostates at experienced laser centres — in which the holmium laser energy is used to enucleate the prostatic adenoma along the true anatomical plane between the adenoma and surgical capsule, delivering complete or near-complete adenoma removal regardless of prostate size. HoLEP has lower blood transfusion rates, shorter catheterisation time, and shorter hospital stay than TURP, with superior long-term durability. However, the HoLEP learning curve is the steepest in endourological surgery and requires dedicated training programmes.

5. Thulium laser vapoenucleation of the prostate (ThuVEP / ThuLEP): A continuous-wave thulium laser alternative to HoLEP with comparable efficacy and a potentially shorter learning curve, increasingly adopted at laser urology centres.

TURP and TUeVP provide well-documented, durable symptomatic relief for BPH that exceeds all currently available medical therapies in terms of magnitude and longevity of effect:

Marked symptom improvement: TURP achieves a mean reduction in IPSS (International Prostate Symptom Score) of 70–85%, from pre-operative scores typically in the moderate-to-severe range (15–25) to post-operative scores in the mild range (3–7). This level of symptom improvement is consistently superior to alpha-blocker therapy (which achieves IPSS reductions of 30–40%) and 5-alpha reductase inhibitors (IPSS reductions of 15–25%).

Improved peak urinary flow rate: Post-operative Qmax increases from a mean of 7–10 mL/s to 20–25 mL/s — a two- to three-fold improvement that substantially exceeds the 2–4 mL/s improvements achievable with medical therapy.

Long-term durability: TURP outcomes are among the most durable of any BPH intervention, with long-term follow-up studies at 10–20 years demonstrating maintained symptomatic benefit. The re-operation rate is approximately 15–20% at 8 years, primarily due to regrowth of residual adenoma tissue or urethral stricture — lower than the medical therapy discontinuation rate due to side effects.

Resolution of retention and obstructive complications: TURP provides definitive decompression of bladder outlet obstruction, resolving acute and chronic urinary retention, reducing post-void residual volumes to below 50 mL in the majority of patients, and enabling catheter-free voiding. Upper tract decompression occurs in patients with hydronephrosis from obstructive uropathy.

Immediate and definitive: Unlike the months to years required for medical therapy to achieve maximum benefit, the symptomatic response to TURP begins within days of catheter removal and reaches full effect within 4–8 weeks.

Cost-effectiveness: Despite the upfront surgical cost, health economic analyses consistently demonstrate that TURP is cost-effective versus indefinite medical therapy over a 5-year horizon in patients with moderate-to-severe LUTS, given medication costs, monitoring visits, and incomplete medical therapy responses.

TURP carries a specific and well-characterised risk profile. Modern bipolar techniques have substantially reduced the most serious complications of the monopolar era, but several risks remain relevant to all techniques:

Retrograde ejaculation: The most common significant side effect of TURP, occurring in 60–90% of patients. During resection, the bladder neck and proximal prostatic urethra are disrupted, causing the ejaculatory mechanism to direct seminal fluid into the bladder during orgasm (retrograde ejaculation) rather than antegrade through the urethra. This does not affect the ability to achieve erection or orgasm (the sensation of orgasm is preserved) but results in azoospermic or dramatically reduced ejaculatory volume. For men who wish to preserve fertility, TURP represents a permanent sterilising effect and alternative fertility-preserving procedures (UroLift, Rezum water vapour therapy) should be discussed in detail before proceeding.

TUR syndrome (monopolar TURP only): Absorption of large volumes of hypotonic irrigating fluid (glycine, sorbitol, or mannitol) through open venous sinuses during monopolar resection causes dilutional hyponatraemia, fluid overload, haemolysis, and in severe cases neurological symptoms (confusion, visual disturbances), cardiovascular compromise, and coma. The risk increases with resection time beyond 60 minutes, large glands, and deep resection. Bipolar TURP using isotonic saline irrigation has essentially eliminated this complication, which is one of the primary reasons bipolar systems are now preferred.

Bleeding and transfusion: Clinically significant bleeding requiring blood transfusion occurs in approximately 2–5% of monopolar TURP cases and 1–3% of bipolar TURP cases. Peri-operative haemoglobin is monitored; symptomatic anaemia is managed with transfusion. Clot retention after TURP may require bladder washout or cystoscopy.

Urethral stricture and bladder neck contracture: Urethral strictures develop in approximately 3–7% of patients, most commonly at the external meatus or bulbar urethra from instrumentation. Bladder neck contracture (scarring at the bladder neck causing new outlet obstruction) occurs in 1–4% of patients and may require endoscopic incision. These are late complications presenting months to years post-operatively as recurrent obstructive symptoms.

Urinary incontinence: Temporary stress urinary incontinence after catheter removal occurs in up to 30% of patients but resolves in the vast majority within 6–12 weeks with pelvic floor exercises. Permanent incontinence requiring pads occurs in approximately 1–2% of patients and is thought to result from damage to the external urethral sphincter complex during resection.

Erectile dysfunction: TURP does not directly damage the neurovascular bundles to the penis, and large meta-analyses show no significant increase in new erectile dysfunction attributable to the resection itself. However, patients with pre-existing erectile dysfunction, diabetes, cardiovascular disease, or age-related decline may experience subjective worsening. Detailed pre-operative assessment and counselling are essential.

Infection and sepsis: Urinary tract infection and, rarely, urosepsis can occur post-operatively. Pre-operative urine culture with targeted antibiotic treatment and prophylactic perioperative antibiotics substantially reduce this risk.

Recovery from TURP and TUeVP follows a predictable course with progressive improvement in urinary symptoms over several weeks. Specific monitoring is required in the immediate post-operative period.

Intra-operative and immediate post-operative period: A urethral catheter (18–22 Fr three-way Foley catheter) is placed at the end of the procedure and continuous bladder irrigation with isotonic saline is maintained to prevent clot retention. The catheter is typically removed at 24–72 hours once the irrigation fluid clears. In patients with large prostates, pre-existing detrusor weakness, or intraoperative complications, the catheter is retained for longer.

Days 1–7 after catheter removal: A transient worsening of urinary frequency, urgency, and dysuria (burning) is virtually universal in the first 1–4 weeks due to mucosal healing within the prostatic urethra. This is distinct from obstructive symptoms and resolves spontaneously. Post-operative haematuria (blood-stained urine) is expected and should clear progressively. Patients are advised to maintain high fluid intake (2–3 litres per day) to keep the urine dilute and reduce clot formation.

Activity restrictions: Strenuous physical activity, heavy lifting, sexual intercourse, and cycling are avoided for 4–6 weeks to minimise the risk of secondary haemorrhage. Secondary bleeding from disruption of healing mucosal slough commonly occurs at 7–14 days post-operatively and usually settles with increased fluid intake and activity restriction. Hospital attendance is required only for clot retention or severe haematuria.

Pelvic floor exercises: Patients are instructed in pelvic floor (Kegel) exercises in the pre-operative or immediate post-operative period to support urinary sphincter recovery and minimise post-operative incontinence. These should be continued for 6–12 weeks.

Clinic follow-up: Review at 6 weeks post-operatively with repeat IPSS score, uroflowmetry, and post-void residual measurement. A successful TURP is defined by an IPSS improvement of greater than 50%, Qmax greater than 15 mL/s, and post-void residual below 100 mL. PSA reassessment at 3 months provides a new post-TURP baseline for prostate cancer surveillance, since TURP removes most of the glandular tissue and the post-TURP PSA level is typically 50% of pre-operative values.

Long-term surveillance: Annual review of symptoms, uroflowmetry, and post-void residual is recommended to detect late bladder neck contracture, urethral stricture, or BPH regrowth. Approximately 15–20% of patients require retreatment at 8 years.

The cost of TURP and TUeVP varies substantially by country, technique, prostate size, and hospital setting. For patients considering medical travel, significant savings are available at accredited centres in multiple countries.

Technique: Monopolar TURP uses the least expensive equipment and is the least costly operative procedure. Bipolar TURP adds modest disposable electrode costs. TUeVP uses a specialised roller electrode. HoLEP, if offered as an alternative at the same centre, requires a holmium laser capital investment that increases procedure costs, though the shorter hospital stay and catheterisation time may offset these costs at a healthcare system level.

Prostate volume: Larger prostates require longer operating time, increasing surgeon, anaesthesia, and theatre costs. Very large glands (greater than 100 mL) may require staged procedures or alternative techniques such as HoLEP or open simple prostatectomy.

Country cost benchmarks: In the United States, TURP including surgeon, anaesthesia, and hospital stay (typically 1–2 nights) ranges from USD 12,000 to USD 25,000. In the United Kingdom under the NHS, TURP is provided without direct patient cost; private surgery ranges from GBP 4,000–8,000. In India (Apollo, Manipal, Fortis hospital networks), Turkey, Thailand, Malaysia, and Mexico at JCI-accredited urology centres, TURP is available for USD 1,500–4,000, representing savings of 75–85% compared to US prices. These packages typically include all hospital fees, surgeon and anaesthesia fees, catheter and irrigation management, and pre-operative investigations.

Post-operative cost considerations: The catheter period (1–3 days), irrigation fluid costs, and post-operative antibiotics add modest costs. In the event of secondary haemorrhage requiring readmission or clot evacuation, additional hospital costs are incurred. The low re-operation rate of TURP (approximately 15–20% at 8 years) makes it cost-effective compared to indefinite medical therapy when modelled over a 5–10 year horizon in health economic analyses.

Medical therapy versus surgery: For patients weighing the lifetime cost of alpha-blocker and 5-alpha reductase inhibitor combination therapy against a one-time TURP, the break-even point typically occurs at 4–6 years in Western healthcare cost models, after which surgical treatment is more economical while also achieving superior symptom control.

A range of medical and surgical alternatives to TURP and TUeVP exist, selected based on prostate size, patient age and comorbidities, desire to preserve ejaculatory function, symptom severity, and access to technology:

Medical management (first-line): Alpha-1 adrenoceptor antagonists (tamsulosin, alfuzosin, silodosin, doxazosin) relax the smooth muscle of the bladder neck and proximal urethra, improving urinary flow within days to weeks. They achieve IPSS reductions of 30–40%. 5-alpha reductase inhibitors (finasteride, dutasteride) shrink the prostate gland by blocking DHT-dependent growth over 6–12 months. They are most effective for prostates greater than 40 mL. Combination therapy (alpha-blocker plus 5-ARI) is the medical gold standard for moderate-to-severe LUTS with large prostates, reducing the risk of acute urinary retention and need for surgery by approximately 60% versus placebo. PDE5 inhibitors (tadalafil 5 mg daily) are approved for LUTS and also address concurrent erectile dysfunction.

Holmium laser enucleation of the prostate (HoLEP): Now considered the emerging gold standard for surgical BPH treatment, particularly for large glands. HoLEP enucleates the adenoma along the anatomical plane of the surgical capsule, achieving the most complete tissue removal of any endoscopic technique regardless of prostate size. Long-term durability at 10 years is superior to TURP. Lower blood transfusion rates, shorter catheterisation time, and shorter hospital stay. The steep learning curve (100–150 cases to achieve expert proficiency) has limited its global adoption, but it is the preferred technique at high-volume laser urology centres worldwide.

UroLift (prostatic urethral lift): A minimally invasive, office-based or short-stay procedure in which nitinol implants are deployed to hold the obstructing lateral prostate lobes away from the urethral lumen without thermal energy or tissue removal. Key advantage: no retrograde ejaculation risk (critical for sexually active men wishing to preserve ejaculatory function). Best suited for prostates less than 70 mL without a prominent obstructing middle lobe. Symptom improvement is less than TURP (IPSS improvement of 40–50%), and re-treatment rates are higher at 5 years (approximately 10–13%).

Rezum water vapour therapy: Convective thermal energy delivered as steam (water vapour at 103°C) via a transurethral needle desiccates obstructing prostatic tissue over 3 months. Office-based under local anaesthesia; ejaculatory function is preserved in approximately 90% of men. Suitable for prostates 30–80 mL. Symptom improvement is durable to 4 years in available data. An emerging option for younger sexually active men or those seeking office-based treatment.

Prostatic artery embolisation (PAE): An interventional radiology procedure in which the prostatic arteries are catheterised via femoral or radial access and microspheres are injected to partially infarct the prostate, causing volume reduction over 3–6 months. Achieves IPSS improvements of 50–60% in carefully selected patients at specialist centres. Ejaculatory function is preserved. Best suited for patients with very large prostates, those who prefer to avoid general anaesthesia, and those in whom surgical approaches carry elevated risk. Not yet recommended as first-line surgical treatment in EAU or AUA guidelines pending longer-term durability data.

Open simple prostatectomy and robot-assisted simple prostatectomy: For very large BPH glands (greater than 80–100 mL) where endoscopic resection is technically challenging or excessively prolonged, open adenomectomy (Millin or Freyer technique) or robot-assisted simple prostatectomy achieves complete adenoma enucleation in a single operation. Re-operation rates are lower than TURP for large-gland BPH, but the procedure carries the risks of open abdominal surgery and longer recovery.